Mirikizumab price and formal purchase channels

Milikizumab (Mirikizumab) is a humanized monoclonal antibody targeting IL-23p19, used to treat moderate to severe inflammatory bowel diseases, includingulcerative colitis and Crohn's disease (CD) . At present, the patent medicine Milizumab has not yet been launched in the Chinese market, so the domestic price is not yet clear, and it is not included in the scope of medical insurance. In overseas markets, the common specifications of Milizumab are 300 mg/15 ml per tube, and the price per box may exceed RMB 10,000. The specific price will fluctuate due to differences in exchange rates, sales regions, and supply channels.

In the international market, there is no generic version of Militizumab on the market, so it is crucial to obtain regular drug channels. Formal channels mainly include officially certified hospitals, international drug distribution agencies or overseas pharmacies to ensure drug quality and reliable sources. Patients should strictly follow the doctor's prescription when using militizumab, and regularly monitor hematological indicators, liver and kidney function, and infection risks to ensure safe use.

The higher price of militizumab is mainly related to the cost of research and development of biologics, production complexity and long-term stability. Its advantage as an IL-23 targeted therapy is to inhibit pro-inflammatory signals, reduce the risk of systemic immunosuppression, and improve long-term disease management effects, thereby improving patients' quality of life. Although expensive, militizumab provides an important treatment option for patients who have failed to respond to traditional drugs, have recurrent symptoms, or have complex complications.

In clinical practice, doctors will formulate a plan based on the patient's condition, previous treatment history, and economic conditions. For patients who require long-term maintenance treatment, the administration method can be flexibly adjusted according to the course of treatment and dosage. For example, intravenous infusion is used to quickly relieve inflammation during the induction period, and subcutaneous injection is used during the maintenance period to facilitate home management. While patients purchase drugs through regular channels, they should also regularly follow up and monitor efficacy indicators in order to adjust the dosage, optimize the treatment plan, and reduce the risk of potential side effects during the course of treatment.

Reference materials:https://omvoh.lilly.com/